ANALGESICS IN FRANCE

Euromonitor International

February 2019

LIST OF CONTENTS AND TABLES

Headlines

Prospects

Codeine Switch To Prescription Medicine Negatively Affects Analgesics

Shift From Opioid Analgesics and New Regulations Impact Future Performance

Competitive Landscape

Intense Competition Between Sanofi and Upsa

A Contrasting Landscape

Category Data

Table 1 Sales of Analgesics by Category: Value 2013-2018

Table 2 Sales of Analgesics by Category: % Value Growth 2013-2018

Table 3 Sales of Topical Analgesics/Anaesthetic by Format: % Value 2013-2018

Table 4 NBO Company Shares of Analgesics: % Value 2014-2018

Table 5 LBN Brand Shares of Analgesics: % Value 2015-2018

Table 6 Forecast Sales of Analgesics by Category: Value 2018-2023

Table 7 Forecast Sales of Analgesics by Category: % Value Growth 2018-2023

Executive Summary

Stagnation for Self-medication

Boom of Sleep Aids, Sports Nutrition, Vitamins and Dietary Supplements

Innovation Is Key To Success

Consumers' Trust in Chemists/pharmacies Is Strong

Future Sales Look Promising Overall But Only Certain Categories Will Grow

Market Indicators

Table 8 Consumer Expenditure on Health Goods and Medical Services: Value 2013-2018

Table 9 Life Expectancy at Birth 2013-2018

Market Data

Table 10 Sales of Consumer Health by Category: Value 2013-2018

Table 11 Sales of Consumer Health by Category: % Value Growth 2013-2018

Table 12 NBO Company Shares of Consumer Health: % Value 2014-2018

Table 13 LBN Brand Shares of Consumer Health: % Value 2015-2018

Table 14 Distribution of Consumer Health by Format: % Value 2013-2018

Table 15 Distribution of Consumer Health by Format and Category: % Value 2018

Table 16 Forecast Sales of Consumer Health by Category: Value 2018-2023

Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2018-2023

Appendix

OTC Registration and Classification

Vitamins and Dietary Supplements Registration and Classification

Self-medication/self-care and Preventive Medicine

Switches

Summary 1 OTC: Switches

Sources

Summary 2 Research Sources

From mid-2017, France’s Ministry of Health and Solidarity requires a prescription for products containing codeine and dextromethorphan. This has led to most adult combination products to be removed from the OTC market. Nevertheless, some adult combination products can still be sold without prescription such as Actron or Isofebril Vitamin C, a combination of acetaminophen and ibuprofen. Consumers are expected to switch to the latter and to non-combination products for 2018 and moving forward.

Euromonitor International's Analgesics in France report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2014-2018, allowing you to identify the sectors driving growth. Forecasts to 2023 illustrate how the market is set to change.

Product coverage: Systemic Analgesics, Topical Analgesics/Anaesthetic.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Analgesics market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.